Please login to the form below

Not currently logged in
Email:
Password:

eliglustat

This page shows the latest eliglustat news and features for those working in and with pharma, biotech and healthcare.

R&D productivity takes off

R&D productivity takes off

Among these, notable examples include PTC Therapeutics' Translarna (ataluren) - the first medicine approved for the treatment of Duchenne muscular dystrophy (DMD) - and Sanofi/Genzyme's Cerdelga (eliglustat) for Gaucher disease, a

Latest news

  • Genzyme's oral Gaucher drug cleared in Europe Genzyme's oral Gaucher drug cleared in Europe

    Cerdelga (eliglustat) has been cleared by the European Commission (EC) for adults living with Gaucher disease type 1, according to Genzyme's parent Sanofi, which says the drug "will be available

  • Orphan drugs in latest CHMP recommendations Orphan drugs in latest CHMP recommendations

    advisers. The Committee for Medicinal Products for Human Use (CHMP) backed Genzyme's Cerdelga (eliglustat) and Boehringer Ingelheim's Ofev (nintedanib) in its latest round of opinions - which are usually followed

  • Sanofi plans 18 new product launches by 2020 Sanofi plans 18 new product launches by 2020

    The remainder of its growth portfolio are Cerdelga (eliglustat) for Gaucher disease - the only approved oral, first-line therapy for the rare genetic disease, Lemtrada (alemtuzumab) for multiple sclerosis and sarilumab,

  • FDA gives green light to Genzyme’s oral Gaucher drug FDA gives green light to Genzyme’s oral Gaucher drug

    Genzyme has said it plans to launch Cerdelga (eliglustat), a drug in the glucosylceramide class, within the next month, giving it an oral therapy to suit alongside its widely-used enzyme ... Cerezyme is already the biggest-selling drug for Gaucher

  • Genzyme on track for eliglustat filing in 2013 Genzyme on track for eliglustat filing in 2013

    The new data puts eliglustat on track for filing this year with approval potentially coming in 2014. ... Genzyme maintains that eliglustat works in a slightly different way which means it is considerably more potent than miglustat.

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics